Varda Space Industries has announced the appointment of pharmaceutical leader Mikael Dolsten to its board of directors. Dolsten has been one of biopharma’s senior R&D leaders, having served for 16 years as Chief Scientific Officer and President of Pfizer R&D, where he oversaw the approval of more than 36 medicines and vaccines and advanced more than 150 drug candidates into clinical studies. Throughout his career, Dolsten has played a role in translating science like Varda’s into approved medicines, guiding programs from discovery through global development, regulatory approval, and commercialization.
“The history of medicine is a history of manufacturing breakthroughs, from fermentation to recombinant proteins; each new environment has expanded what was possible. Varda has built the infrastructure to make orbital manufacturing reliable and repeatable, and I am excited to help translate that capability into medicines that make a difference for patients,” said Varda board member Mikael Dolsten.
The first space-made product for Earth will be a pharmaceutical, and Varda will be the first to utilize microgravity to deliver pharmaceutical drugs to benefit patients. Due to the absence of gravity, materials such as the active pharmaceutical ingredients in medicines behave differently than they would on Earth, enabling formulations that would otherwise be impossible to achieve. The company’s goal has been for in-space pharmaceutical processing to become a normal, reliable part of the drug development pipeline. Varda stated it was the only company with the launch cadence, reentry capability, and pharmaceutical science team to bring routine space manufacturing to market.
